A next generation bioscience company

Corporate Presentation
01
Company Overview

02
Diagnostics

03
Therapeutics

04
Appendix
Diagnostics
Lead product is a rapid point-of-care COVID-19 RT-PCR diagnostic test launched in Europe in April 2021. Diagnostic development pipeline includes a portfolio of real-time ultra low-cost infectious disease biosensors.

Drug Delivery
Platform technology to develop innovative cost-effective transdermal and oral dissolvable formulations of generic, hybrid-generic, and new active pharmaceutical ingredients.

Drug Development
4 late-stage neurology therapeutics in clinical development and 2 psychedelic medicine programs.
Buy and Build Strategy

XPhyto’s buy and build strategy is creating a portfolio of late-stage therapeutic and diagnostic products.

- **2017**: XPhyto Founded
- **12. 2018**: BUNKER Pflanzenextrakte GmbH Acquisition
- **09. 2019**: Vektor Pharma TF GmbH Acquisition
- **04. 2020**: 3a-diagnostics GmbH Exclusive Agreement
- **02. 2021**: University of Alberta & Leading German University Collaborations
- **02. 2021**: Two psychedelic medicine collaborations underway with leading institutions in Germany and Canada
- **02. 2021**: Rapid, low-cost pathogen screening tests for pandemic and oral health applications
- **02. 2021**: Experts in thin film drug delivery systems for transdermal and oral dissolvable dosage forms
- **02. 2021**: Near-term focus on development and clinical validation of cannabis extract “kits” for pharmaceutical compounding in Germany

A next generation bioscience company | XPhyto Therapeutics Corporation
### Therapeutics

<table>
<thead>
<tr>
<th>Indication</th>
<th>Design and development</th>
<th>Feasibility study</th>
<th>Final validation</th>
<th>CE-Mark</th>
<th>Market</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parkinson’s Disease</td>
<td>Rotigotine – TDS</td>
<td></td>
<td></td>
<td></td>
<td>Q1 2021</td>
</tr>
<tr>
<td>Epilepsy, other</td>
<td>Cannabidiol (CBD) – ODF</td>
<td></td>
<td></td>
<td></td>
<td>Q2 2021</td>
</tr>
<tr>
<td>Nausea / Anorexia, other</td>
<td>Tetrahydrocannabinol (THC) – ODF</td>
<td></td>
<td></td>
<td></td>
<td>Q3 2021</td>
</tr>
<tr>
<td>MS assoc. spasticity, other</td>
<td>CBD:THC combination (1:1) – ODF</td>
<td></td>
<td></td>
<td></td>
<td>Q4 2021</td>
</tr>
</tbody>
</table>

### Diagnostics

<table>
<thead>
<tr>
<th>Indication</th>
<th>Design and development</th>
<th>Feasibility study</th>
<th>Final validation</th>
<th>CE-Mark</th>
<th>Market</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19</td>
<td>Rapid RT-PCR</td>
<td></td>
<td></td>
<td></td>
<td>Q2 2021</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Ultra-rapid LFA</td>
<td></td>
<td></td>
<td></td>
<td>Q3 2021</td>
</tr>
<tr>
<td>Infectious disease (multiple)</td>
<td>Peptide biosensor – ODF</td>
<td></td>
<td></td>
<td></td>
<td>Q4 2021</td>
</tr>
<tr>
<td>Oral health (multiple)</td>
<td>Peptide biosensor – ODF</td>
<td></td>
<td></td>
<td></td>
<td>Q4 2021</td>
</tr>
</tbody>
</table>

**Notes:**
- TDS: transdermal patch; ODF: oral dissolvable film
- XPhyto Therapeutics Corporation
- A next generation bioscience company
- Q1 2021, Q2 2021, Q3 2021, Q4 2021
Diagnostics
COVID-19 RT-PCR Diagnostic Test
Commercial Launch April 2021

- Rapid test in 25 minutes
  5 min hands-on time and 20 mins reaction only

- Point-of-care diagnostic device
  for use with minimal lab equipment

- Low detection limit
  diagnostic reliability of PCR tests

- Cost-effectiveness
  enables broad testing

- Easily accessible
## Diagnostic Pipeline

<table>
<thead>
<tr>
<th>Diagnostics</th>
<th>Indication</th>
<th>Design and development</th>
<th>Feasibility study</th>
<th>Final validation</th>
<th>CE-Mark</th>
<th>Market</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapid RT-PCR</td>
<td>COVID-19</td>
<td></td>
<td></td>
<td>Q2 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ultra-rapid LFA</td>
<td>COVID-19</td>
<td></td>
<td></td>
<td>Q3 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peptide biosensor – ODF</td>
<td>Infectious disease (multiple)</td>
<td></td>
<td></td>
<td>Q4 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peptide biosensor – ODF</td>
<td>Oral health (multiple)</td>
<td></td>
<td></td>
<td>Q4 2021</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**RAPID & Ultra rapid new medical device products**

Initial launch in Europe

State funding

USD $39.1 billion

*The global rapid test market* is projected to reach USD $39.1 billion by 2023 with a **CAGR of 8.9%**
Therapeutics 03
## Therapeutic Pipeline

<table>
<thead>
<tr>
<th>Therapeutics</th>
<th>Indication</th>
<th>Formulation and development</th>
<th>Preclinical study</th>
<th>Clinical study</th>
<th>Market</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rotigotine – TDS</td>
<td>Parkinson’s Disease</td>
<td></td>
<td></td>
<td>Q1 2021</td>
<td></td>
</tr>
<tr>
<td>Cannabidiol (CBD) – ODF</td>
<td>Epilepsy, other</td>
<td></td>
<td></td>
<td>Q2 2021</td>
<td></td>
</tr>
<tr>
<td>Tetrahydrocannabinol (THC) – ODF</td>
<td>Nausea / Anorexia, other</td>
<td></td>
<td></td>
<td>Q3 2021</td>
<td></td>
</tr>
<tr>
<td>CBD:THC combination (1:1) – ODF</td>
<td>MS assoc. spasticity</td>
<td></td>
<td></td>
<td>Q4 2021</td>
<td></td>
</tr>
</tbody>
</table>

**New formulation**
- Of already approved drugs

**Improvement**
- Of pharmacokinetics, drug compatibility, application

**Low development risk**

**Initial approval and launch**
- In Europe

**USD $29.2 billion**
- The global thin film drugs market is expected to grow to USD $29.2 billion by 2024 at a CAGR of 10.5%.*

---

TDS: transdermal patch; ODF: oral dissolvable film; *Market Data Forecast, Arcview Market Research

---

A next generation bioscience company | XPhyto Therapeutics Corporation
Recent Developments

Business Highlights
Exclusive development partnership with 3a-Diagnostics GmbH
Acquisition of Vektor Pharma TF GmbH
Exclusive psychedelic API production partnerships

Therapeutic Pipeline
Transdermal - Rotigotine TDS
Oral Dissolvable - CBD, THC, and CBD:THC

Non-dilutive Funding
Funding from German Federal Ministry of Education and Research for development of real-time ultra low-cost biosensors for high-risk pandemic threats such as influenza, swine flu and avian flu.

Diagnostic Pipeline
COVID-19 PCR Test launched Q2, 2021
Oral biosensors launch Q4, 2021

Psychedelic Medicine
Exclusive development deal with Canadian University for industrial scale synthesis of pharmaceutical grade Mescaline.
Exclusive development deal with German University for industrial scale biotech production of pharmaceutical grade Psilocybin.

Outlook
Investment Highlights

World-class drug delivery expertise
A pipeline of novel thin-film drug delivery formulations, offering precise, efficient, optimized bioavailability

Disruptive diagnostic pipeline
Rapid, point-of-care diagnostic and screening tests for infectious diseases and oral health indications

Near-term market & exit opportunities
A late-stage pipeline of proprietary diagnostics and drug delivery innovations

Efficient M&A execution
Management committed to building shareholder value through buy & build strategy

R&D collaborations
Leveraging world-class academic expertise and state-of-the-art facilities in Germany and Canada with limited capital investment

Unique Psychedelic Programs
First-mover advantage and industry leadership in the development of industrial scale production of pharmaceutical grade psilocybin and mescaline
Market Overview

Thin film products

Global thin film drugs market is expected to grow to USD $29.2 billion by 2024 at a CAGR of 10.5%.A

Key players are MonoSol Rx, Tesa Labtec GmbH, Pfizer, Inc., Novartis AG, and Wolters Kluwer, Solvay, Allergan plc, Sumitomo Dainippon Pharma Co., Ltd., IntelGenx Corp, and Transition Therapeutics, Inc.²

Disease indication: Schizophrenia, Migraine, Opioid Dependence, Nausea & Vomiting

Rapid-diagnostic test

The global rapid test market is projected to reach USD $39.1 billion by 2023 with a CAGR of 8.9%.C


COVID-19 test

The global COVID-19 diagnostics market size is estimated at USD 19.8 billion in 2020.D

The global COVID-19 diagnostics market is expected to grow at a compound annual growth rate of 3.1% from 2021 to 2027 to reach USD 24.6 billion by 2027.

Until today approx. 14.5 mil COVID-19 tests have been applied in Germany.E


A: Arcview Market Research; B: Maximize Market Research; C: Allied Market Research; D: Grand View Research; E: Statista
Management and team

Hugh Rogers
LLB CEO & director
Lawyer, B.Sc
Extensive experience in venture capital

Christopher Ross
CPA, CFO

Prof. Dr. Raimar Löbenberg
Director
Founder and director of the drug development and innovation center, faculty of pharmacy and pharmaceutical science, university of Alberta, Canada
Co-founder of RS Therapeutics Inc.

Wolfgang Probst
Director & managing director
Management consultant specialized in investment consulting and capitalization.
Expert in mergers and acquisitions, corporate reorganizations, and divestitures.

Prof. Dr. Thomas Beckert
Managing director
Founder and managing director of Vektor Pharma
Experienced in formulation and machine development for thin film delivery systems

Prof. Dr. Wolfgang Eisenreich
Executive advisor
Research group leader in the department of chemistry, TUM
More than 20-year experience in metabolic pathways and signaling cascade in pathogen-host interaction

Manfred Buchberger
Head of Corp. Development
Expert in the medical and diagnostics products industry
Almost a decade of experience as a CEO and global management board member of a €600 Mio revenue diagnostics manufacturer.
Bioscience company with proven therapeutics and innovative diagnostics approaching the market.

Made in Germany